TheMETproto-oncogene encodes a pivotal tyrosine kinase receptor, binding the hepatocyte growth factor (HGF, also known as scatter factor, SF) and governing essential biological processes such as organogenesis, tissue repair, and angiogenesis. The pleiotropic physiological functions of MET explain its diverse role in cancer progression in a broad range of tumors; genetic/epigenetic alterations ofMETdrive tumor cell dissemination, metastasis, and acquired resistance to conventional and targeted therapies. Therefore, targeting MET emerged as a promising strategy, and many efforts were devoted to identifying the optimal way of hampering MET signaling. Despite encouraging results, however, the complexity of MET’s functions in oncogenesis yields intriguing observations, fostering a humbler stance on our comprehension. This review explores recent discoveries concerningMETalterations in cancer, elucidating their biological repercussions, discussing therapeutic avenues, and outlining future directions. By contextualizing the research question and articulating the study’s purpose, this work navigates MET biology’s intricacies in cancer, offering a comprehensive perspective.
MET原癌基因编码一种关键的酪氨酸激酶受体，其与肝细胞生长因子（HGF，亦称扩散因子SF）结合，调控器官发生、组织修复和血管生成等重要生物学过程。MET的多效性生理功能解释了其在多种肿瘤进展中的多样化作用；MET的遗传/表观遗传改变驱动肿瘤细胞扩散、转移以及对常规和靶向治疗的获得性耐药。因此，靶向MET成为一种有前景的策略，众多研究致力于寻找抑制MET信号传导的最佳途径。尽管取得了鼓舞人心的成果，但MET在肿瘤发生中功能的复杂性带来了引人深思的观察结果，促使我们以更审慎的态度看待当前的理解。本综述探讨了关于癌症中MET改变的最新发现，阐明其生物学影响，讨论治疗途径，并概述未来方向。通过阐明研究问题并明确研究目的，本文梳理了MET在癌症生物学中的复杂性，提供了一个全面的视角。
An Observatory for theMETOncogene: A Guide for Targeted Therapies
肿瘤(癌症)患者之家